1	Monoallelic CRMP1 gene variants cause neurodevelopmental disorder
2	Ethiraj Ravindran, ^{1-3§} Nobuto Arashiki, ^{4§} Lena-Luise Becker, ^{1-3#} Kohtaro Takizawa, ^{4#}
3	Jonathan Lévy, ^{5,6} Thomas Rambaud, ⁶ Konstantin L. Makridis, ¹⁻³ Yoshio Goshima, ⁷ Na Li, ⁸
4	Maaike Vreeburg, ⁹ Bénédicte Demeer, ^{10, 11} Achim Dickmanns, ¹² Alexander P.A Stegmann, ⁹
5	Hao Hu, ^{8*} Fumio Nakamura, ^{4*} Angela M. Kaindl ^{1-3*}
6	
7	Author affiliations:
8	¹ Department of Pediatric Neurology, Charité–Universitätsmedizin Berlin, Berlin, 13353,
9	Germany.
10	² Center for Chronically Sick Children, Charité–Universitätsmedizin Berlin, Berlin, 13353,
11	Germany.
12	³ Institute for Cell Biology and Neurobiology, Charité–Universitätsmedizin Berlin, Berlin,
13	10117, Germany.
14	⁴ Department of Biochemistry, Tokyo Women's Medical University, Tokyo, Sinjuku-ku, 162-
15	8666, Japan.
16	⁵ Department of Genetics, APHP-Robert Debré University Hospital, Paris, 75019, France.
17	⁶ Laboratoire de biologie médicale multisites Seqoia - FMG2025, Paris, 75014, France
18	⁷ Department of Molecular Pharmacology and Neurobiology, Graduate School of Medicine,
19	Yokohama City University, Yokohama, Kanazawa-ku, 236-0004, Japan.
20	⁸ Laboratory of Medical Systems Biology, Guangzhou Women and Children's Medical Center,
21	Guangzhou Medical University, 9 Jinsui Road, 510623, Guangzhou, China.
22	⁹ Clinical Genetics, Maastricht University Medical Center, Maastricht, 6202, Netherlands.

1

23	¹⁰ Center	for	Human	Genetics,	CLAD	Nord	de	France,	CHU	Amiens-Picardie.	Amiens,

24 80054, France

¹¹CHIMERE EA 7516, University Picardie Jules Verne, Amiens, France

¹²Department of Molecular Structural Biology, Institute for Microbiology and Genetics

27 (GZMB), Georg-August-University Göttingen, Göttingen, 37077, Germany

28

30

31 Corresponding authors:

- 32 Professor Dr. Angela M. Kaindl, Charité Universitätsmedizin Berlin, Campus Virchow-
- 33 Klinikum, Augustenburger Platz 1, 13353 Berlin. Tel / Fax: +49 30 450 566301 /7566301.
- 34 Email: angela.kaindl@charite.de*.
- 35 Professor Fumio Nakamura, Tokyo Women's Medical University, Department of
- 36 Biochemistry, 8-1 Kawada-cho, Sinjuku-ku, Tokyo, Japan. 162-8666 Tel / Fax: +81-3-5269-
- 37 7415. Email: nakamura.fumio@twmu.ac.jp**.
- 38 Dr. Hao Hu, Laboratory of Medical Systems Biology, Guangzhou Women and Children's
- 39 Medical Center, Guangzhou Medical University, 9 Jinsui Road, 510623, Guangzhou, China.

40 Tel / Fax: +86 (0)20 38076326/265. Email: huh@cougarlab.org**.

- 41
- 42 **Running title:** CRMP1 and neurodevelopmental disorder

43

Keywords: CRMP1; brain development; intellectual disability; autism spectrum disorder;
neurodevelopmental disorder.

²⁹ *, *, * These authors contributed equally to this work.

- 46 Email addresses: ethiraj.ravindran@charite.de, arashiki.nobuto@twmu.ac.jp, lena-
- 47 luise.becker@charite.de, takizawa.kohtaro@twmu.ac.jp, jonathan.levy@aphp.fr,
- 48 thomas.rambaud@laboratoire-seqoia.fr, konstantin.makridis@charite.de,
- 49 goshima@yokohama-cu.ac.jp, lina@cougarlab.org, m.vreeburg@mumc.nl,
- 50 demeer.benedicte@chu-amiens.fr, adickma@gwdg.de, sander.stegmann@mumc.nl,
- 51 huh@cougarlab.org, nakamura.fumio@twmu.ac.jp, angela.kaindl@charite.de

52

53 Abstract

54 Collapsing response mediator proteins (CRMPs) are key for brain development and function. Here, we link CRMP1 to a neurodevelopmental disorder. We report heterozygous de novo 55 56 variants in the *CRMP1* gene in three unrelated individuals with muscular hypotonia, 57 intellectual disability and/or autism spectrum disorder. Based on in silico analysis these 58 variants are predicted to affect the CRMP1 structure. We further analyzed the effect of the 59 variants on the protein structure/levels and cellular processes. We showed that the human 60 *CRMP1* variants are dominant-negative and impact the oligomerization of CRMP1 proteins. 61 Moreover, overexpression of mutant-CRMP1 variants affect neurite outgrowth of murine 62 cortical neurons. While altered CRMP1 levels have been reported in psychiatric diseases, 63 genetic mutation in *CRMP1* gene has never been linked to human disease. We report for the 64 first-time mutations in the *CRMP1* gene and emphasize its key role in brain development and 65 function by linking directly to a human neurodevelopmental disease.

66 Introduction

67 Neurodevelopment is a fine-tuned process orchestrated by distinct expression and function of several genes and any disturbances in this timely-controlled process culminate in 68 neurodevelopmental disorder.^{1,2} Collapsin response mediator proteins (CRMP) are cytosolic 69 phosphoproteins that are highly and differentially expressed in the nervous system.^{3,4} The five 70 CRMP subtypes (CRMP1-5) form homo- or hetero-tetramers in various combinations and 71 thereby enable distinct functions key for neurodevelopment.⁵ Targeted neurodevelopmental 72 73 processes include cell migration, axonal outgrowth, dendritic branching, apoptosis mediated through extracellular signaling molecules (Sema3A, reelin, neurotrophins).⁶⁻¹⁰ CRMP 74 75 function is regulated in a spatiotemporal manner through protein phosphorylation mediated by various kinases such as Cdk5, Rho/ROCK, and GSK3.^{11,12} 76

Given their key function in developmental processes, disturbances in CRMP function can result in neurodevelopmental diseases (NDD). In this line, monoallelic *CRMP5* variants can cause Ritscher-Schinzel syndrome 4 (MIM#619435), a neurodevelopmental disease with craniofacial features, cerebral and cardiovascular malformations, and cognitive dysfunction.¹³ *CRMP4* variants have been associated with amyotrophic lateral sclerosis in the French population.¹⁴

83 Here, we link for the first time CRMP1 variants in three unrelated pedigrees to neurodevelopmental disorder in humans with muscular hypotonia, autism spectrum disorder 84 85 (ASD) and/or intellectual disability. In humans, maternal CRMP1 autoantibodies have been 86 associated with autism in their children, and increased CRMP1 mRNA levels were identified in individuals with schizophrenia, attention deficit hyperactivity disorder and ASD.^{15,16} 87 88 Knockout of *Crmp1* in mice results in schizophrenia-associated behavior, impaired learning and memory, and prepulse inhibition.¹⁷ On a cellular level, abnormal neurite outgrowth, 89 90 dendritic development and orientation, and spine maturation of cortical and/or hippocampal neurons have been shown.⁷⁻⁹ Loss of Crmp affects long-term potentiation maintenance.⁹ In 91

5

92	addition, ce	rebellar develo	pment and its l	loss leads to	o reduced g	granule cell proli	feration,
93	apoptosis, ai	nd migration in	the cerebellum	of $Crmp1^{-/-}$	mice. ¹⁰ Alth	ough evidence of	n altered
94	levels of CR	MP1 in neurop	psychiatric disea	ses exists, th	e mutations	s in the CRMP1 g	gene has
95	not	been	linked	to	a	human	disease.

96 Subjects and methods

97 Written informed consent was obtained from all parents of the patients to participate in this 98 study and publish the data of this research work. The human study adhered to the World 99 Health Association Declaration of Helsinki (2013) and was approved by the local ethics 100 committees of the Charité (approval no. EA1/212/08). All animal experimental protocols were 101 checked and approved by the Institutional Animal Care and Use Committee of the Tokyo 102 Women's medical University with protocol No. 'AE21-086'. All animal experiments were 103 performed at daytime. The study was not pre-registered.

104 Genetic analyses. In family 1, DNA samples of family members were isolated from 105 peripheral blood lymphocytes, and whole exome sequencing (WES) was performed on a 106 HiSeq XTen Deep Sequencer (Illumina, CA, USA), with an average coverage of ~36X, 107 according to the manufacturer's instructions. The primary data analysis was done by a 108 combination of Burrows-Wheeler Alignment (BWA) sequence aligner for reads alignment to 109 human reference genome GRCh37/hg19, Genome Analysis Toolkit (GATK) pipeline for calling single-nucleotide variant (SNV), and small insertion and deletion (indel), and 110 ANNOVAR for variant characterization ¹⁸⁻²⁰. Identified variants were filtered through 111 112 comparison with the disease-associated variants in the known databases (Human Gene 113 Mutation Database (HGMD, 2020.2) and the Online Mendelian Inheritance in Man (OMIM)) and polymorphism databases (dbSNP143, 1000 Genome). Sanger sequencing of the CRMP1 114 115 gene (NM 001014809) was performed to confirm the identified variants in the patients and 116 further family members and performed segregation analysis of the variants with the 117 phenotype.

In family 2, variants were detected by routine WES diagnostics and variant calling using a parent-offspring trio approach as described previously ²¹. Briefly, the exome was captured using the Agilent SureSelectXT Human All Exon v5 library prep kit (Agilent Technologies,

7

121 Santa Clara, CA, USA). Exome libraries were sequenced on an Illumina HiSeq 4000 122 instrument (Illumina, San Diego, CA, USA) with 101 bp paired-end reads at a median 123 coverage of $75 \times$ at the BGI Europe facilities (BGI, Copenhagen, Denmark). Sequence reads 124 were aligned to the hg19 reference genome using Burrows-Wheeler Alignment (BWA) and 125 variants were subsequently called by the Genome Analysis Toolkit (GATK) unified 126 genotyper, version 3.2-2 and annotated using a custom built diagnostic annotation pipeline. 127 Multi-species sequence alignment were performed using Multialin, PhyloP and PhastCons 128 and the variants disease- causative nature were predicted using the free online tool Mutation 129 Taster (www.mutationtaster.org).

130 In family 3, trio-based whole-genome sequencing was performed on blood-derived genomic 131 DNA at the Laboratoire de biologie médicale multisites SeqOIA (LBMS SeqOIA, Paris, 132 France). After extraction, DNA samples were sonicated, and libraries were prepared using the 133 NEBNext Ultra-II kit (New England Biolabs). Whole-genome sequencing was performed in 134 paired-end 2x150-bp mode, with a NovaSeq6000 (Illumina). Demultiplexed data were aligned 135 to the genomic reference (hg19). Recalibration and variant calling was performed using 136 GATK4 (Broad Institute). Short variants were annotated with SNPeff (4.3t). Copy Number 137 Variants >4kb were called using CNV nator (v0.4.1) and annotated with AnnotSV (v2.5.1). 138 An average depth-of-coverage of >50x was obtained for both probands, and variants were 139 prioritized according to impact, frequency, and segregation. Sanger sequencing was 140 performed to confirm the identified mutation in the CRMP1 gene.

Expression and purification of recombinant *hCRMP1* variants. Subcloned GST-tagged *CRMP1B*-V5 expression plasmids (wildtype, P475L, T313M) were transformed into *E. coli*BL21 (DE3) pLysS cells (BioDynamics Laboratory, Tokyo, Japan). These bacteria were
harvested to 200 ml Terrific Broth medium (Invitrogen, Waltham, MA, USA) including 100
mg/ml ampicillin (Sigma, St. Louis, MO, USA). After incubation for 1.5 h at 37 °C, the

146 protein production was induced by 0.1 mM isopropyl β -D-1-thiogalactopyranoside (Sigma) 147 for 18 h at 20 °C. Collected bacteria by centrifugation were suspended in 24 ml 148 homogenization buffer (H buffer; 50 mM Tris/HCl (pH 8.0), 100 mM KCl, 1 mM EDTA, 5% 149 glycerol, 1% NP-40, 1 mM DTT) and then sonicated 4 times for 5 min on ice using Ultrasonic 150 Homogenizer (Microtec Co., LTD., Chiba, Japan). After centrifugation at 12,000 rpm for 30 151 min at 4 °C, resultant supernatants were mixed with 400 µl of Glutathione Sepharose 4FF 152 resin (Cytiva, Tokyo, Japan) and gently inverted for 24 h at 4 °C. The resins were collected 153 and washed 4 times with 10 ml H buffer, and then washed 5 times with 1 ml cleavage buffer 154 (C buffer; 20 mM Tris/HCl (pH 8.0), 150 mM NaCl, 0.1% NP-40, 1 mM DTT). The pelleted 155 resins were suspended in 100 µl of C buffer including 10 U PreScission protease (Cytiva) and 156 incubated for 24 h at 4 °C with constant agitation. These mixtures were transferred to the filter cups (Vivaclear Mini 0.8 µm PES; Sartorius, Stonehouse, UK), and the flow through fractions 157 158 were obtained by centrifugation at 10,000 rpm for 1 min at 4 °C. Protein concentrations were 159 determined using the Bradford reagent (Thermofisher scientific, Waltham, MA, USA), and 160 the purified mutants were assessed by SDS-PAGE.

161 Determination of dominant-negative effect of the CRMP1 variants on the multimer 162 formation of the wild type. HEK293T cells were co-transfected with pc3.1beta2-V5-163 CRMP1B-wildtype and either one of myc-tagged CRMP1B constructs (wildtype, P475L or 164 T313M). After 24h incubation, the cells were harvested by modified C buffer (20 mM 165 Tris/HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 1 mM DTT, protease inhibitor cocktail 166 (cOmplete mini; Roche)), sonicated for 15 min, and centrifuged at 15,000 rpm for 30 min at 4 167 °C. Electrophoresis of the resultant supernatants under the native and denaturing state were 168 performed as described above. Semi-dry Western transfers were carried out at 15 V for 60 169 min using the transfer buffer, 50 mM Tris, 40 mM glycine, 20% methanol, 0.1% SDS. In the 170 case of the BN-PAGE, the transferred membranes were incubated in 8% acetic acid for 15

171 min, washed by ultrapure water, and then dried completely, followed by decolorization using 172 100% methanol. After blocking by 5% skim milk in TBS-T (20 mM Tris/HCl (pH 7.4), 150 173 mM NaCl, 0.1% Tween-20) for 60 min, the membranes were reacted with anti-myc (9E10) 174 mAb (1:2,000, FUJIFILM, Cat No. 011-21874) or anti-V5 mAb (1:10,000, Invitrogen 175 (R960–25) RRID: AB_2556564) for overnight at 4 °C. Infrared-fluorescence- (IRDye 680RT; 176 LI-COR, Lincoln, NE, USA) or HRP-conjugated (Dako, Santa Clara, CA, USA) secondary 177 antibodies were utilized for the detection of the first antibodies on the membranes obtained 178 from the native or denatured electrophoresis, respectively.

179 Transfection to primary cultured mouse embryonic cortical neurons. Pregnant ICR 180 (RRID:IMSR TAC:icr) female mice were purchased from Nihon SLC (Shizuoka, Japan). 181 Overdose isoflurane (7 - 8%)/air mixture was inhaled to euthanize the pregnant ICR mice 182 until the loss of breathing. The E15-16 mouse embryos dissected from the pregnant mice were 183 immediately placed in ice-cold PBS and euthanized by decapitation. Cortices dissected from 184 the embryos were treated with 1% trypsin/PBS at 37 °C for 5 min and quenched with the 185 addition of 0.5% trypsin inhibitor. The dissociated neurons were centrifuged at 800 xg for 5 min at 4 °C, washed once, and suspended in DMEM-10% FBS. The cells (1.0×10^6) were 186 187 transfected with 10 µg of pc3.1beta2-V5 harboring *CRMP1B*-wildtype, -P475L, or -T313M or 188 using an electroporation equipment NEPA21 (NEPA GENE, Chiba, Japan). The condition of 189 electroporation was follows: Poring pulse (275 V, 0.5 ms pulse length, 50 ms pulse interval, 190 10% decay, +pulse orientation, 2 times); Transfer pulse (20 V, 50 ms pulse length, 50 ms 191 pulse interval, 40% decay, ±pulse orientation, 5 times). The cells were suspended in DMEM-10% FCS and seeded $(1 \times 10^4/\text{well})$ on a 24 well culture-plate coated with 0.05 mg/ml of 192 193 poly-l-lysine (Wako, Cat No. 163-19091). After overnight incubation, the medium was 194 replaced with Neurobasal medium supplemented with 2% B-27, 2 mM Glutamax, 50 U/ml 195 penicillin, and 50 µg/ml streptomycin (500 µl/well) and incubated 37 °C for 6–7 days.

196 **Immunocytochemistry of mice cortical cultured neurons.** The primary cultured cortical 197 neurons were fixed with 4% paraformaldehyde (PFA)/PBS for 30 min at 25 °C, replaced with 198 PBS, and stored at 4 °C. As the expression of V5-CRMP1B constructs was limited, tyramide 199 signal amplification (TSA) system (PerkinElmer, Cat No. NEL700A001KT) was applied for 200 the detection of V5 signal. Briefly, the cells were treated with PBS containing 0.3% H₂O₂ for 201 20 min at 25 °C and blocked with 1:1 mixture of PBS supplemented with 0.1% Triton X-100 202 (PBST) containing 10% skim milk and Tris-buffered serine supplemented with 0.1% Triton 203 X-100 (TBST) containing 5% normal goat serum (NGS) for 30 min at 25 °C. The cells were 204 washed twice with TBST and incubated with the primary antibody mixture consisting of 205 TBST 2.5% NGS, anti-V5 mouse mAb (1:5000) and anti-MAP2 rabbit pAb (1:5000, Covance 206 (PRB-547C) RRID: AB_2565455) for overnight at 4 °C. The cells were sequentially 207 incubated each for 1h at 25°C with TBST 2.5% NGS containing biotin-conjugated anti-mouse 208 secondary antibody (1:3000, Jackson) and TBST 2.5% NGS containing streptavidin-HRP 209 conjugate (1/500, dilution, PerkinElmer). Then the cells were reacted with tyramide signal 210 amplification mixture for 10min at 25°C and subsequently incubated with TBST 2.5% NGS 211 containing streptavidin-Alexa594 (1:2000) and anti-rabbit secondary antibody-Alexa488 for 2 212 h at 25 °C. The images of immunostained neurons were captured by an Olympus IX70 213 microscope equipped with x10 Objective lens and DP74 camera. The neurite outgrowth of 214 V5- or tdTomato- positive neurons was scored with Fiji software (2.0.0-rc-59/1.51n). In each 215 condition, 13 to 20 V5- or tdTomato-positive neurons were analyzed.

216 **Results**

217 Phenotype and genotype of index patients

218 Proband 1 (P1) was born as the second child of non-consanguineous healthy parents of 219 Caucasian descent after an uneventful pregnancy (Fig 1A, Table 1). At delivery a singular 220 umbilical artery was noted. The global development was delayed from infancy on: with sitting 221 at 1.5-2 years-of-age, standing with support at 1-1.5 years-of-age, walking at 2-2.5 years-of-222 age, first words at 2-2.5 years-of-age. Standardized cognitive tests performed at 5-10 years 223 revealed a moderate intellectual disability with an intelligence quotient (IQ) of 55 at last 224 assessment using the Kaufman Assessment battery for children (K-ABC). She had speech 225 disorder. Behavioral problems included a lack of distance to men and a sexualized behavior. 226 At last assessment at 15-16 years-of-age, the girl had generalized muscular hypotonia with 227 normal reflexes, but fine motor problems with a broad-based gait but no ataxia. When 228 climbing stairs, she showed clear instability. The results of cranial magnetic resonance 229 imaging (MRI) at 1.5 - 4 years as well as that of further work-up (including metabolic tests, 230 electroencephalogram (EEG). ophthalmological assessment, electrocardiogramm, 231 echocardiogramm, abdominal sonography) were normal. Since preliminary genetic tests 232 including chromosome analysis and array-CGH were normal in the index patient (P1), we 233 performed whole exome sequencing (WES) to identify the underlying genetic cause. WES 234 followed by bioinformatic analysis and confirmation with Sanger sequencing revealed the 235 heterozygous de novo variant in the CRMP1 gene c.1766C>T (NM_001014809.2; Chr4 236 (GRCh37):g.5830253G>A) in the affected child P1 (Fig 1B). At the protein level, this variant 237 leads to an amino acid change at position 589 from proline to leucine: P589L in long isoform, 238 CRMP1A (NP_001014809.1) and P475L in short form, CRMP1B (NP_001304.1) (Fig 1B). 239 The identified variant was not found in 1000Genomes, dbSNP or gnomAD. The CADD score 240 (https://cadd.gs.washington.edu/) was 24.5. The mutation localizes to a highly conserved 241 position, as demonstrated by PhyloP (5.327), PhastCons (1) score and multi-species sequence 12

alignment (Fig 1C). The Provean score of the identified variants predicted to have a
deleterious effect (-5.854, cutoff= -2.5).

244 Proband 2 (P2) was born as the second child of non-consanguineous parents of Caucasian 245 descent after an uneventful pregnancy and delivery (Fig 1A, Table 1). The boy was 246 macrosomic at birth but had no congenital microcephaly. His motor development was delayed 247 (unsupported walking at 2-2.5 years-of-age) due to congenital mild muscular hypotonia with 248 normal deep tendon reflexes, but no coordination problems. He had bilateral pes planus. A 249 speech delay and language impairment with first words spoken at 3-3.5 years-of-age were 250 diagnosed. He was also diagnosed with an autism spectrum disorder and normal cognitive 251 abilities (IQ 95). At last assessment at 10-11 years-of-age, an obesity associated with 252 hyperphagia was of raising concern, and he had secondary enuresis nocturna. The results of a 253 cranial MRI and EEG were normal. Similarly, through WES followed by bioinformatic 254 analysis, we identified a heterozygous de novo variant c.1280C>T in the CRMP1 gene 255 (NM_001014809.2; Chr4 (GRCh37):g.5841279G>A) in proband (P2) (Fig 1B). This variant 256 leads to an exchange of threenine to methionine at position 427 in the long form, CRMP1A 257 (p.T427M, NP 001014809.1) and at position 313 in the short form, CRMP1B (p.T313M, 258 NP_001304.1) (Fig 1B). The variant affects a highly conserved region of the protein (Fig 259 **1C**).

260 Proband 3 (P3) is the first child of three of a non-consanguineous family of European 261 descent (Fig 1A, Table 1). She was born at gestation week 40 after an uneventful pregnancy, 262 with normal birth parameters (weight: 3.610 kg, height: 50 cm, head circumference: 32.5cm, 263 Appar score: 10/10). She had developmental delay with not being able to sit alone at 1-1.5 264 years-of-age and walked without support at 2-2.5 years-of-age. Her speech development was 265 delayed with few words spoken at 2.5-3 years-of-age. She began to gain weight from 1.5-2 266 years-of-age, and overgrowth was noticed since the 2-2.5 years-of-age. Endocrinological 267 screening, including leptin blood level was normal. There is familial history of obesity on

268 both parental sides, and one of the parent is macrocephalic. She developed severe behavioral 269 issues with temper tantrums, stubbornness, hyperphagia, obsessive-compulsive characteristics 270 and autism spectrum disorder. She was attending medical-educational institute at the age of 8-271 8.5 years. At the last assessment of 13-14 years-of-age, she had moderate intellectual 272 disability and persistent severe behavioral disorders. Distinctive facial features were low 273 forehead hair insertion, anteverted and large earlobes, broad nasal tip, short philtrum and full 274 lower lips. Genu valgum and hyperlordosis as well as abdominal and dorsal strech marks were 275 noted. Enuresia was noted. Cerebral MRI and abdomino-renal ultrasound were normal. 276 Metabolics and storage disease screening were negative. Array analysis revealed two 277 maternally inherited deletions: a 668 kb deletion at 3q26.31 and a 371kb at 5q23.1, confirmed 278 by genome sequencing and considered as variant of unknown significance. Further analysis 279 through trio-based whole-genome sequencing identified a *de novo* variant in the *CRMP1* gene 280 c.1052T>C (NM_001014809.2; Chr4 (GRCh37):g.5841409A>G) (Fig 1B). The identified 281 variant leads to an exchange of phenyl alanine to serine at position 351 of long form of 282 CRMP1 (CRMP1A (NP_001014809.1)) and at position 237 in short form (CRMP1B 283 (NP 001304.1)) and it is located in the highly conserved region of the protein (Fig 1C). This 284 variant is not found in gnomAD database. In silico pathogenicity prediction tools predicts the 285 identified variants to be deleterious (CADD pared: 23.60; REVEL 0.577 (Thresholds > 0.5) 286 Damaging), ClinPred 0.975 (Damaging ≥ 0.5), Mistic: 0.90 (Damaging Threshold ≥ 0.5)). No 287 additional pathogenic variants have been identified by trio genome sequencing, including all 288 known genes involved in neurodevelopmental disorder.

289 Effect of identified CRMP1 variants on protein structure

290 Since CRMP1 is known to oligomerize to form homotetramers and heterotetramers along 291 with other CRMPs to regulate cellular functions, we determined the effect of the identified 292 human variants on its protein structure using known structures and protein structure prediction

tools. The structure of CRMP1 short form, CRMP1B, has been determined at 3.05A 293 resolution²² lacking the N-terminal 14 residues and residues 491-572 in their C-terminal 294 295 region. CRMP1 monomer consists of three structural parts, N-terminal β -strands followed by 296 a linker β -strand connected to the central α/β -barrel (Fig 1D). Several residues contribute to 297 the oligomerization interface of CRMP1 and the quaternary structure of CRMP1 tetramer is 298 shown in Fig 1E. The amino acid exchange of P475L, T313M, and F237S are located in the 299 highly conserved region of CRMP1. The P475L is the last residue before the start of the C-300 terminal helix and the exchange of proline to leucine is predicted to lead to serious clashes 301 with the neighboring residues (Fig 1F). Such spatial constraints may alter the dipole moment 302 of the helix and lead to long-range allosteric effects (Fig 1G). The T313M lies within the 303 region of the α/β -barrel, is oriented towards the inside of the protein and located close to the 304 ligand-binding active site/cavities (Fig 1H). Rearrangements within the protein upon 305 interaction with other CRMPs or molecules could shuffle these cavities for normal 306 functioning. The exchange of threonine to methionine is predicted to prevent rearrangements 307 and to affect the oligomerization as well as other interactions. The F237S is localized directly 308 in the center of interface 1 so the exchange of a heavy hydrophobic sidechain by a hydrophilic 309 short sidechain most likely interferes with the stability of the dimer interaction (Fig 1I). Based 310 on structural simulations, all three variants are predicted to affect the ternary structure of 311 CRMP1 and impact on its oligomerization.

312 P475L and T313M mutations affect homo-oligomerization of CRMP1B

To analyze the effect of *CRMP1* variants on its protein levels and cellular function, two variants (CRMP1B-P475L (P1) or -T313M (P2)) were chosen for further functional analysis. We purified the recombinant human CRMP1B-wildtype, -P475L (P1) or -T313M (P2) proteins using the *E. coli* GST-tag expression system. CRMP1B-wildtype showed two major 64 kDa and 60 kDa bands on SDS-denatured gel electrophoresis (**Fig 2A, left lane**). The 64

318 kDa and 60 kDa correspond to full-length CRMP1B and to a truncated, C-terminal region 319 cleaved form, respectively. The yield of purified T313M (TM) or P475L (PL) was less than 320 that of wildtype in the same condition (Fig 2A, middle and right lanes). This finding may be 321 due to lower expression and/or aggregation of the mutant proteins in E. coli. As T313M and 322 P475L mutated residues are positioned close to the dimer/tetramer interface of CRMP1B, 323 these mutations may affect homo-oligomerization of CRMP1. We therefore examined the 324 oliogomerization of recombinant CRMP1 preparation with Blue-Native gel electrophoresis 325 (Fig 2B). A broad band of CRMP1B-wildtype was present at high (720 kDa) but residual 326 amount of monomeric form was detected at low molecular weight (70 kDa) on Blue-Native 327 gel. The 720 kDa band probably represents the homo-oligomerization of CRMP1B-wildtype 328 under the native condition. In contrast, CRMP1B-T313M and -P475L showed the increased monomeric 70 kDa band, suggesting weakened self-association of these mutants. 329

330 As these mutations were found in the heterozygous state in the affected patients, CRMP1B-331 T313M and/or -P475L expression might perturb the oligomerization of CRMP1B-wildtype in 332 a dominant-negative manner. We therefore next co-expressed V5-CRMP1B-wildtype together 333 with either myc-CRMP1B-wildtype, -T313M, or -P475L in HEK293T cells. As shown in Fig. 334 **2C** upper and middle panels, co-expression of myc-*CRMP1B*-T313M or -P475L did not alter 335 the expression level of V5-CRMP1B-wildtype on SDS-denatured gel electrophoresis. Anti-336 V5 immunoblot analysis of these specimens on Blue-Native gel electrophoresis (Fig 2C, 337 lower panel) revealed that the co-expression of myc-CRMP1B-wildtype showed major 1100 338 kDa and minor 360 kDa bands of V5-CRMP1-wildtype. In contrast, co-expression of myc-339 CRMP1B-T313M or -P475L increased the lower (360 kDa) V5-CRMP1B-wildtype, 340 suggesting that these mutants potentially impede multimer formation of CRMP1B-wildtype. 341 As V5-immunoreactive signal at higher molecular size (1100 kDa) in P475L was remarkably 342 decreased than that in T313M, P475L may exhibit stronger dominant negative effect.

16

343 **P475L and T313M mutations attenuate neurite outgrowth of cortical neurons**

344 We next asked whether the ectopic expression of CRMP1B mutants in primary cultured 345 murine cortical neurons affect the neuronal development. Dissociated E15 mouse cortical 346 neurons were electroporated with the expression vector harboring either V5-CRMP1B-347 wildtype (wt), -T313M (TM), -P475L (PL), or tdTomato. The cells were seeded onto PLLcoated culture dishes and grown for 6-7 days. After fixation, the cells were immunostained 348 349 with anti-V5 and anti-MAP2 antibodies. We found that the longest primary neurites of V5-350 CRMP1B-T313M or -P475L transfected neurons were shorter than those of V5-CRMP1B-351 wildtype (wt) or tdTomato transfected cells (Fig 3A-D). We then measured the length of the 352 longest primary neurite from V5- or tdTomato-positive neurons in each condition. The longest 353 primary neurites expressing CRMP1B-T313M or -P475L were 40-50% shorter than those 354 expressing CRMP1B-wildtype (wt) (Fig 3E). As the longest primary neurites of the cultured 355 cortical neurons is thought to be axons, these CRMP1B mutants may interfere with the 356 oligomerization of CRMP1 in turn to attenuate the outgrowth of the cortical axons.

357 **Discussion**

In this study, we report the human phenotype associated with heterozygous *CRMP1* variants in three affected children of unrelated non-consanguineous pedigrees. All the patients have a neurodevelopmental disorder with motor delay and muscular hypotonia. While patient P1 has moderate intellectual disability and behavioral abnormalities, P2 was diagnosed with an autism spectrum disorder but a normal cognitive profile and P3 presented with moderate intellectual disability and autism spectrum disorder.

We showed that those human *CRMP1* variants have a dominant-negative effect and impact the oligomerization of CRMP1 proteins. CRMP1 exists as homo- or hetero-tetramers to interact with various signaling molecules and to link microtubules to subcellular structures and regulate cytoskeletal dynamics.^{5,23} In line with this, CRMP1 colocalizes to the mitotic spindles and centrosomes, indicating of playing a key role in mitosis and cell cycle progression.²⁴ Defective cell cycle, abnormal mitotic spindle and centrosomes are the common key pathomechanism underlying several neurodevelopmental disorders.²⁵

371 Dysregulation of other CRMPs that have been linked to human disease has been shown to 372 affect specific cellular processes associated with the clinical phenotype. For example, mutant 373 CRMP5 impedes the ternary complex formation with microtubule-associated protein 2 374 (MAP2) and beta-III-tubulin, thereby causing a defective inhibitory regulation on neurite 375 outgrowth and dendritic development and thereby contribute to the brain malformation phenotype.¹³ MAP2 has been already reported to play a key role in neurite outgrowth and 376 377 synaptic plasticity through its role in microtubule stabilization and cytoskeletal association.^{26,27} Also, mutant CRMP4 was shown to affect axonal growth and survival of 378 motor neurons and thereby contribute to the amyotrophic lateral sclerosis phenotype.¹⁴ In this 379 380 study we showed that the identified *CRMP1* variants affect neurite outgrowth, which is a characteristic phenotype associated to many neurodevelopmental/psychiatric disorders.²⁸ Our 381 382 finding is in line with the reduced neurite outgrowth phenotype and impaired long-term 18

potentiation in the $Crmp1^{-/-}$ mice.⁹ Mechanistically, these cellular processes are regulated in a 383 384 spatiotemporal manner through CRMP1 phosphorylation by several kinases such as Cdk5, 385 Rho/ROCK or GSK3, and any disturbances in these kinases or mutation of specific residues culminates in the abnormal brain development.^{6,8-11,29} In the case of $Cdk5^{-/-}$ mice, abnormal 386 dendritic spine morphology was shown in cortical neurons as it was in Crmp1^{-/-} mice. 387 388 Intriguingly, both mouse models show schizophrenia-like behavior, indicating the commonly shared cellular mechanism for dendritic development.^{9,30} In the context of neuronal 389 390 development, defective phosphorylation of tyrosine residues in CRMP1 by Fyn-mediated Reelin signaling impairs cortical neuron migration.⁶ Over the last two decades, new 391 392 phosphorylation specific sites in CRMP1 are being reported and recently, phosphorylation of Tyr504 residue by Fyn has been shown to play an important step in Sema3A-regulated 393 dendritic development of cortical neurons.³¹ As a future perspective, it will be interesting to 394 395 find other CRMP1 variants and elucidate the role of specific residues in various neuronal 396 process and associate with the phenotypic spectrum of neurodevelopmental disorder.

In conclusion, we report for the first time human *CRMP1* mutations, link them to a human neurodevelopmental disease and highlight underlying pathomechanisms. Our report adds *CRMP1* to list of other *CRMP* genes linked to neurological disorders and underlines the important role of CRMP1 in the nervous system development and function.

401 **Declaration of interest**

402 The authors declare no competing interests.

403

404 **Data availability**

All methods applied in this project are described in detail in the 'Materials andMethods'section and the original data are presented as source file

407

408 Acknowledgements

409 The authors thank the index families for their participation in this study. We acknowledge 410 Petra Bittigau, Akosua Sarpong for attending the patients; Anna Tietze for the analysis of cranial MR images; Sabrina Pommer and Jessica Fassbender for technical assistance; Piotr 411 412 Neumann for assistance in data interpretation and lively discussions; Dr. Tanabe Kenji and 413 Dr. Fumitoshi Saitoh for electroporation equipment. We acknowledge the funding resources for this study: German Research Foundation (SFB665, SFB1315, FOR3004, AMK), the 414 415 Sonnenfeld Stiftung (AMK, KLM), the Berlin Institute of Health (BIH, CRG1, AMK), the 416 Charité (AMK, ER, LLB, KLM), and by grants-in-aid for Scientific Research from the Japan 417 Society for the Promotion of Science (JSPS) (16K07062) (FN).

418 **References**

1. Rice D, Barone S, Jr. Critical periods of vulnerability for the developing nervous
system: evidence from humans and animal models. *Environ Health Perspect*. Jun 2000;108
Suppl 3:511-33. doi:10.1289/ehp.00108s3511

422 2. Gilbert SL, Dobyns WB, Lahn BT. Genetic links between brain development and
423 brain evolution. *Nat Rev Genet*. Jul 2005;6(7):581-590. doi:10.1038/nrg1634

3. Strittmatter L-HWaSM. A Family of Rat CRMP Genes Is Differentially Expressed in
the Nervous System. *J Neurosci* 1996;16:6197–6207

426 4. Bretin S, Reibel S, Charrier E, et al. Differential expression of CRMP1, CRMP2A,
427 CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. *J Comp*428 *Neurol.* May 23 2005;486(1):1-17. doi:10.1002/cne.20465

429 5. Wang LH, Strittmatter SM. Brain CRMP forms heterotetramers similar to liver
430 dihydropyrimidinase. *J Neurochem.* Dec 1997;69(6):2261-9. doi:10.1046/j.14714159.1997.69062261.x

432 6. Yamashita N, Uchida Y, Ohshima T, et al. Collapsin response mediator protein 1
433 mediates reelin signaling in cortical neuronal migration. *J Neurosci*. Dec 20
434 2006;26(51):13357-62. doi:10.1523/JNEUROSCI.4276-06.2006

7. Naoya Yamashita AM, Yutaka Uchida, Fumio Nakamura, Hiroshi Usui, Toshio
Ohshima, Masahiko Taniguchi, Jérôme Honnorat, Nicole Thomasset, Kohtaro Takei, Takuya
Takahashi, Pappachan Kolattukudy, Yoshio Goshima. Regulation of spine development by
semaphorin3A through cyclin-dependent kinase 5 phosphorylation of collapsin response
mediator protein 1. *J Neurosci*

440 2007 (Nov 14;27(46):12546-54)

8. Hiroko Makihara SN, Wataru Ohkubo, Naoya Yamashita, Fumio Nakamura, Hiroshi
Kiyonari , Go Shioi , Aoi Jitsuki-Takahashi , Haruko Nakamura, Fumiaki Tanaka , Tomoko
Akase, Pappachan Kolattukudy , Yoshio Goshima CRMP1 and CRMP2 have synergistic but
distinct roles in dendritic development. *Genes Cells*. 2016;Sep;21(9):994-1005.

Su KY, Chien WL, Fu WM, et al. Mice deficient in collapsin response mediator
protein-1 exhibit impaired long-term potentiation and impaired spatial learning and memory. *J Neurosci*. Mar 7 2007;27(10):2513-24. doi:10.1523/JNEUROSCI.4497-06.2007

Charrier E, Mosinger B, Meissirel C, et al. Transient alterations in granule cell
proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1-/- mice. *Genes Cells*. Dec 2006;11(12):1337-52. doi:10.1111/j.1365-2443.2006.01024.x

Uchida 451 Yutaka Yukio Sasaki,Hiromi 11. TO, Suzuki, Shigeki Yanai, Naoya 452 Yamashita, Fumio Nakamura, Kohtaro Takei, Yasuo Ihara, Katsuhiko Mikoshiba, Papachan 453 Kolattukudy,Jerome Honnorat,Yoshio Goshima. Semaphorin3A signalling is mediated via 454 sequential Cdk5 and GSK3^β phosphorylation of CRMP2: implication of common 455 phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes to 456 *Cells* 2005;(10,165–179)

Yoshimura T, Kawano Y, Arimura N, et al. GSK-3beta regulates phosphorylation of
CRMP-2 and neuronal polarity. *Cell.* Jan 14 2005;120(1):137-49.
doi:10.1016/j.cell.2004.11.012

Jeanne M, Demory H, Moutal A, et al. Missense variants in DPYSL5 cause a
neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities. *Am J Hum Genet*. May 6 2021;108(5):951-961. doi:10.1016/j.ajhg.2021.04.004

463 14. Blasco H, Bernard-Marissal N, Vourc'h P, et al. A rare motor neuron deleterious
464 missense mutation in the DPYSL3 (CRMP4) gene is associated with ALS. *Hum Mutat*. Jul
465 2013;34(7):953-60. doi:10.1002/humu.22329

466 15. Braunschweig D, Krakowiak P, Duncanson P, et al. Autism-specific maternal
467 autoantibodies recognize critical proteins in developing brain. *Transl Psychiatry*. Jul 9
468 2013;3:e277. doi:10.1038/tp.2013.50

Bader V, Tomppo L, Trossbach SV, et al. Proteomic, genomic and translational
approaches identify CRMP1 for a role in schizophrenia and its underlying traits. *Hum Mol Genet.* Oct 15 2012;21(20):4406-18. doi:10.1093/hmg/dds273

17. Naoya Yamashita AT, Keizo Takao, Toshifumi Yamamoto, Pappachan Kolattukudy,
Tsuyoshi Miyakawa, Yoshio Goshima. Mice lacking collapsin response mediator protein 1
manifest hyperactivity, impaired learning and memory, and impaired prepulse inhibition. *Front Behav Neurosci.* 2013 (Dec 27;7:216.)

476 18. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler
477 transform. *Bioinformatics*. Mar 1 2010;26(5):589-95. doi:10.1093/bioinformatics/btp698

478 19. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants
479 from high-throughput sequencing data. *Nucleic Acids Res.* Sep 2010;38(16):e164.
480 doi:10.1093/nar/gkq603

Mark A DePristo EB, Ryan Poplin, Kiran V Garimella, Jared R Maguire, Christopher
Hartl, Anthony A Philippakis, Guillermo del Angel, Manuel A Rivas, Matt Hanna, Aaron
McKenna, Tim J Fennell, Andrew M Kernytsky, Andrey Y Sivachenko, Kristian Cibulskis,
Stacey B Gabriel, David Altshuler & Mark J Daly A framework for variation discovery and
genotyping using next-generation DNA sequencing data. *Nature Genetics*. 2011;(43,
pages491–498 (2011))

487 21. de Ligt J, Willemsen MH, van Bon BW, et al. Diagnostic exome sequencing in
488 persons with severe intellectual disability. *N Engl J Med.* Nov 15 2012;367(20):1921-9.
489 doi:10.1056/NEJMoa1206524

Liu SH, Huang SF, Hsu YL, et al. Structure of human collapsin response mediator
protein 1: a possible role of its C-terminal tail. *Acta Crystallogr F Struct Biol Commun.* Aug
2015;71(Pt 8):938-45. doi:10.1107/S2053230X15009243

Antipola 23. Nakamura F, Kumeta K, Hida T, et al. Amino- and carboxyl-terminal domains of
Filamin-A interact with CRMP1 to mediate Sema3A signalling. *Nat Commun.* Oct 31
2014;5:5325. doi:10.1038/ncomms6325

496 24. Shih JY, Lee YC, Yang SC, et al. Collapsin response mediator protein-1: a novel
497 invasion-suppressor gene. *Clin Exp Metastasis*. 2003;20(1):69-76.
498 doi:10.1023/a:1022598604565

Zaqout S, Kaindl AM. Autosomal Recessive Primary Microcephaly: Not Just a Small
Brain. *Front Cell Dev Biol*. 2021;9:784700. doi:10.3389/fcell.2021.784700

501 26. Kaech S, Parmar H, Roelandse M, Bornmann C, Matus A. Cytoskeletal
502 microdifferentiation: a mechanism for organizing morphological plasticity in dendrites. *Proc*503 *Natl Acad Sci U S A*. Jun 19 2001;98(13):7086-92. doi:10.1073/pnas.111146798

Sanchez C, Diaz-Nido J, Avila J. Phosphorylation of microtubule-associated protein 2
(MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. *Prog Neurobiol.* Jun 2000;61(2):133-68. doi:10.1016/s0301-0082(99)00046-5

Prem S, Millonig JH, DiCicco-Bloom E. Dysregulation of Neurite Outgrowth and Cell
Migration in Autism and Other Neurodevelopmental Disorders. *Adv Neurobiol*. 2020;25:109153. doi:10.1007/978-3-030-45493-7_5

S10 29. Yamashita N, Goshima Y. Collapsin response mediator proteins regulate neuronal
development and plasticity by switching their phosphorylation status. *Mol Neurobiol*. Apr
S12 2012;45(2):234-46. doi:10.1007/s12035-012-8242-4

513 30. Yamashita N, Takahashi A, Takao K, et al. Mice lacking collapsin response mediator 514 protein 1 manifest hyperactivity, impaired learning and memory, and impaired prepulse 515 inhibition. *Front Behav Neurosci.* 2013;7:216. doi:10.3389/fnbeh.2013.00216

S16 31. Kawashima T, Jitsuki-Takahashi A, Takizawa K, et al. Phosphorylation of Collapsin
Response Mediator Protein 1 (CRMP1) at Tyrosine 504 residue regulates Semaphorin 3Ainduced cortical dendritic growth. *J Neurochem.* May 2021;157(4):1207-1221.
doi:10.1111/jnc.15304

520 **Table 1: Phenotype of patients with** *CRMP1* **variants.**

521

Characteristics and Symptoms	Proband 1 (Pedigree 1)	Proband 2 (Pedigree I1)	Proband 3 (Pedigree I1I)
<i>CRMP1</i> variant	o 1766C∖T:	a 1080C>T	a 1052T∖C
(NM_001014809.2);	C.1/00C>1;	c.1200C>1;	c.10521>C;
(NP_001014809.1)	p.r 569L	p.14271v1	p.1.5515
Parents	non-	non-	non-
	consanguineous	consanguineous	consanguineous
Gender	female	male	female
Anthropometric data	normal	normal	Overgrowth
weight (kg)	57.1 (0.15 SD)	N/A	133 (14.2 SD)
height (cm)	168 (0.43 SD)		166.5 (2.94 SD)
OFC (cm)	53.5 (-1.02 SD)		62 (5 SD)
Pregnancy, birth, postnatal			
adaption	normal	normal	normal
singular umbilical artery	+	-	-
macrosomia	-	+	-
fetal fingerpads	-	+	-
Microcephaly (OFC < -2 SD)	-	-	-
Macrocephaly (OFC >-2 SD)	-	-	+ (5 SD)
Facial dysmorphism	-	-	+
Delayed motor development	+	+	+
walking unsupported (years)	2-2.5	2-2.5	2-2.5
Global muscular hypotonia	mild	mild	mild
Deep tendon reflexes	normal	normal	normal
Intellectual disability	moderate (IQ 55)	no (IQ 95)	moderate
Autism spectrum disorder	-	+	-
Behavioral problems			
lack of distance, sexualized	+	+	+
behavior	+	-	-
hyperphagia	-	+	+
Delayed speech and language			
development	(2,2,5)	(2, 2, 5)	(2, 2, 5)
(first words spoken) (years)	(2-2.3)	(3-3.3)	(3-3.3)
Fine motor problems	+	-	+
Other			
secondary enuresis			
nocturna	-	+	+
pes planus	-	+	-
obesity	-	+	+
EEG results	normal	normal	normal
Cranial MRI abnormalities	-	-	-

522 +, yes; -, no; IQ, intellectual quotient; N/A, not available; OFC, occipitofrontal

523 circumference; SD, standard deviation

524 Figure Legends:

525 Fig 1: Genotype of patients with variants in CRMP1. A. Pedigree of index families. B. 526 Pictogram representing the CRMP1 cDNA with identified variant of proband 1 (P1) in exon 527 12 (c.1766C>T, NM_001014809.2) which leads on protein level to an amino acid change of proline to leucine in CRMP1 (CRMP1A-long form (p.P589L, NP_001014809.1) and 528 529 CRMP1B-short form (p.P475L, NP 001304.1)); the variant in proband 2 (P2) in exon 9 530 c.1280C>T (NM_001014809.2) leads to an exchange of threonine to methionine (CRMP1A 531 (p.T427M, NP 001014809.1) and CRMP1B (p.T313M, NP 001304.1)); the variant in 532 proband 3 (P3) in exon 6 c.1052T>C (NM_001014809.2) leads to an exchange of phenyl 533 alanine to serine (CRMP1A (p.F351S, NP_001014809.1) and CRMP1B (p.F237S, 534 NP 001304.1)). C. Multi-species sequence alignment localizes the variants in the highly 535 conserved area of CRMP1. D. The short form CRMP1 monomer is composed of three 536 structural parts, an N-terminally located 7 β -strands forming two β -sheets (depicted in blue), 537 followed by a linker β -strand (yellow) connecting to the central α/β -barrel (cyan/magenta) 538 formed by 7 repeats. Inserted after repeat 4 are 2 additional α -helices (gray) E. CRMP1 539 assembles into tetramers. The relevant sites of mutation T313M, P475L and F237S are 540 indicated as sphere model, with the T313 and F237 located in the central channel in the 541 vicinity of the interaction sites and P475L is locates at the beginning of the C-terminal helix 542 and oriented towards the adjacent molecules. F. The mutation P475L reveals serious clashes 543 with neighboring residues (red hexagonals) which may be accounted for by a shift of the helix 544 as shown in (G). H. Detailed representation of the structural vicinity of the T313M (yellow) 545 to the ligand-binding cavity (magenta). **I.** Magnified view of interface 1 tilted 90 ° backwards 546 complex with respect to panel E highlighting the arrangement of the two phenylalanines at 547 position 237 from the neighboring units. The exchange of phenylalanine with hydrophobic

residues to serine with hydrophilic side chain interferes with the stability of the interaction ininterface 1.

550 Fig 2. Attenuated oligomer formation of CRMP1-P475L and CRMP1B-T313M mutants. 551 A. Purified CRMP1B-wildtype, -T313M, and -P475L recombinant proteins on SDS- PAGE 552 stained with CBB. GST-tagged CRMP1 were expressed in *E. coli* and purified through the 553 binding to glutathione resin and the digestion with PreScission protease. Equal volume (2.5 554 μ l) of the purified specimens, which were prepared in the same condition, were loaded on the 555 gel. The yield of the mutants was less than that of CRMP1-wildtype as shown in panel. Two 556 major 64 kDa and 60 kDa bands in the preparations are full-length and truncated form, 557 respectively. **B.** Estimation of the multimeric state under native condition. Bacterially 558 expressed and purified CRMP1B specimens (5 g) were electrophoresed on NativePAGE 559 Novex 4-16% Bis-Tris gel in the presence of CBB-G250. The gel was stained with CBB-560 R250 to visualize separated proteins. CRMP1B-wildtype exhibited major 720 kDa and minor 561 70 kDa bands, which respectively represent homo-oligomer and monomer. In contrast, 562 CRMP1B-T313M and -P475L showed predominant 70 kDa bands, suggesting that the 563 mutations may interfere with the homo-oligomerization of CRMP1. C. Dominant negative 564 effect of T313M and P475L mutant on the oligomerization of CRMP1B-wildtype. HEK293T 565 cells co-expressing V5-CRMP1B-wildtype and either one of myc-CRMP1B-wildtype, -566 T313M, or -P475L were analyzed. Anti-V5 and anti-myc immunoblot analyses of the 567 specimens subjected to SDS-PAGE showed that the expression level of V5-CRMP1 and myc-568 CRMP1 in each condition was similar extent (upper and middle panels). Anti-V5 immunoblot 569 analysis of these specimens on Blue-Native gel electrophoresis is shown (lower panel). Co-570 expression of V5-CRMP1B-wildtype and myc-CRMP1B-wildtype exhibited major 1100 kDa 571 and minor 360 kDa V5-reactive bands. In contrast, co-expression of myc-CRMP1B-T313M 572 or -P475L increased the lower (360 kDa) V5-reactive band. This suggests that co-expression

573	of these mutants may interfere with multimer formation of V5-CRMP1B-wildtype.
574	Abbreviations: CRMP1B-wildtype, wt; CRMP1B-T313M, TM; CRMP1B-P475L, PL
575	Fig 3. Attenuated neurite outgrowth by the ectopic expression of CRMP1B- P475L and
576	CRMP1B-T313M mutants. A-D. Representative images of the neurons expressing V5-
577	CRMP1B-wildtype (A), -T313M (B), -P475L (C), or tdTomato (D). Transfected neurons
578	were visualized by anti-V5 immunostaining or tdTomato expression (red) and anti-MAP2
579	immunostaining (green). The longest primary neurites of the neurons expressing V5-
580	CRMP1B-T313M or -P475L were shorter than those of the neurons transfected with V5-
581	CRMP1B-wildtype or tdTomato. Scale bars, 100 μ m. E. Longest primary neurite length. The
582	length of the longest primary neurite from V5- or tdTomato-positive neurons was scored in
583	each condition. The graph represents average \pm SEM with individual values from four
584	independent experiments. The number of examined neurons in each condition is CRMP1B-
585	wildtype, 66; -T313M, 64; -P475L, 49; tdTomato, 73. Data were analyzed by one-way
586	ANOVA followed by Tukey's post-hoc test. $**p < .01$, $***p < .001$.

Author contributions. AMK and FN were responsible for project conception. AMK, MV, BD analyzed and interpreted patient's clinical data. LLB and KLM contributed clinical information by gathering clinical information and written informed consents. HH, NL, APAS, JL, TR performed WES and bioinformatics data analysis. ER performed Sanger sequencing and segregation analysis. NA, KT and FN performed functional experiments. AD performed structural prediction analysis. ER and AMK drafted the manuscript that was revised and accepted by all coauthors.







V5/tdTomato MAP2